Potential Clinical and Economic Impact of Statin Formulary Management
|
|
- Harry Daniels
- 7 years ago
- Views:
Transcription
1
2 Potential Clinical and Economic Impact of Statin Formulary Management Karol E. Watson, MD Summary The evidence is clear that aggressive management of cardiac risk factors is beneficial and generally safe for the majority of patients. For the many patients who require medication to achieve their goals, drug selection should be based, first and foremost, on evidence of impact on morbidity and mortality outcomes. In addition to efficacy, safety, cost, and practical patient related concerns need to be considered. Key Points Early, sustained, goal-oriented optimization of cardiovascular risk factors is important. It s important to base drug selection on evidence of morbidity and mortality benefits. All costs, not just medications, must be considered when considering a formulary change. The impact of a change on patient compliance must also be considered. THE GOAL OF PREVENTIVE CARDIOLOGY is to maximize event reduction in patients with,or at risk for, heart disease.a wealth of epidemiologic evidence is available on risk factors, causes of heart disease, and interventions to prevent heart disease. Optimal management of cardiac risk factors includes early, sustained clinical goal optimization, compliance with medication,and non-pharmacological measures.clinical goal optimization is achieving nationally accepted guideline values for blood pressure, glucose, and lipids. Almost everyone in American society needs nonpharmacologic measures to reduce cardiac risk factors. When patients need additional help reaching their goals, drug therapy is important. Drug selection should be based, first and foremost, on evidence of impact on morbidity and mortality outcomes. In addition to efficacy, safety, cost, and practical patient related concerns need to be considered. Atherosclerosis begins silently in the teenage years. It starts with a thickening of the endothelial layer of the blood vessel.the process of ongoing changes and lipid accumulation within the blood vessel continues throughout a person s lifetime. By the third decade of life, a person may have perceptible thickening of the artery wall. As the process continues untreated, an advanced atherosclerotic lesion develops that may rupture, thereby forming a blood clot and obstructing blood flow that results in a heart attack or a stroke. Previously it was thought that patients could only be helped to survive a heart attack. With current evidence-based therapies, intervention can occur much earlier to slow the progression of atherosclerosis. Some data now suggest that the process can even be halted or reversed. Major Cardiovascular Risk Factors The four major risk factors for developing heart disease are hyperlipidemia, hypertension, cigarette smoking, and diabetes. Eighty-seven to 100 percent of patients in one study experiencing a fatal coronary event had at least one of these risk factors before dying. 1 About 80 percent of patients with coronary heart disease have at least one of these four major risk factors contributing to their development. 2 Most hypertensive patients have at least one additional risk factor and many have several other risk factors (Exhibit 1). 3 For men, hypertension, plus an additional risk factor, occurs in 2 percent of patients. Hypertension plus two risk factors occur in 25 percent of males. Hypertension and three risk factors occur in 22 percent. A small 18 Journal of Managed Care Medicine Vol. 9, No. 4
3 Exhibit 1: Most Hypertensive Patients Have Additional Risk Factors 2 Framingham Offspring (Ages 18 to 74 Years) with Hypertension Were Likely to Have Additional Risk Factors MEN WOMEN HTN +1 RF HTN +2 RFs HTN +1 RF HTN +2 RFs 2% 25% 27% 24% HTN only 19% 8% 22% HTN +3 RFs HTN only 17% 12% 20% HTN +3 RFs RF=risk factor HTN +4 or more RFs HTN +4 or more RFs Exhibit 2: Impact of Elevated Systolic BP and Total Cholesterol on CHD Mortality MRFIT 3 34 Age-Adjusted CHD Death Rates Per 10,000 Person-years MRFIT N=202, Cholesterol Quintile (mg/dl) MRFIT=Multiple Risk Factor Intervention Trial <182 < Systolic BP Quintile (mm Hg) percentage of men have four risk factors. Multiple risk factors occur more often in women.thus, it is unusual for patients to have hypertension alone. It appears that risk conferred by each individual risk factor is not just additive, but probably multiplicative as illustrated by data from the MRFIT intervention trial (Exhibit 2). 3 Dyslipidemia is one of the cardiac risk factors for which much success in reducing cardiac events has been achieved. The lower low-density cholesterol (LDL-C) that is achieved, the lower the cardiovascular event rate, regardless of age, gender, history of heart attack, or starting cholesterol values. 4 This relationship between LDL-C lowering and cardiovascular event reduction from large, randomized, well-designed trials is shown in Exhibit Implications of Switching Statins As statins become widely available generically, many managed care plans have revised their lipid-lowering agent formularies. When these changes are made, several issues in addition to efficacy need to be addressed, including actual overall costs of switching thousands of patients therapy, compliance issues, and comparative safety of the various statins. Switching formulary agents results in more expense than just medication costs. A managed care plan must also consider the cost of additional medical visits and laboratory tests likely to occur as the result of any switch. Many clinicians will want to see a patient after a switch is made and run lipid profile and liver function tests to ensure the patient is effectively and safely Vol. 9, No. 4 Journal of Managed Care Medicine 19
4 Exhibit 3: The Reduction in CHD Risk Is Proportional to the Percent of LDL-C Lowering ALLHAT-LLT LRC-CPPT A to Z TNT LIPID WOSCOPS CARE HPS LIPS ASCOT 4S Prove-It % Change in LDL- Cholesterol ALLHAT-LLT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial); LRC-CPPT (Lipid Research Clinics Coronary Primary Prevention Trial); A to Z (Aggrastat to Zocor); TNT (Treating to New Targets); LIPID (Long-term Intervention with Pravastatin in Ischemic Disease); WOSCOPS (West of Scotland Coronary Prevention Study); CARE (Cholesterol and Recurrent Events); HPS (Heart Protection Study); LIPS (Lescol Intervention Prevention Study); ASCOT (Anglo- Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm); 4S (Scandinavian Simvastatin Survival Study); PROVE-IT (Atorvastatin Evaluation and Infection Therapy) managed on the new agent.an example of estimates of switch-related costs are presented in Exhibit 4. This analysis used a national plan coverage policy as a basis for cost determination and a commercial payment rate (140 percent of the 200 Medicare Physician Fee Schedule). Based on six additional services occurring because of a switch (two physician visits, cholesterol panel, liver function test, and venipuncture), this analysis projects that for every 10,000 patients switched from one statin to another, the average cost would be greater than $800,000. These estimated initial medical costs have to be weighed against the potential cost savings of any statin change. Another issue to be addressed is the impact on compliance and persistence. One study conducted in a managed care setting attempted to determine the effect of switching medications on the compliance and persistence of new statin users. A retrospective analysis of a pharmacy claims database provided by a large PBM was conducted. 17 The study sample consisted of 38,000 new statin users age 18 to 5 receiving atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Mevacor), pravastatin (Pravachol), or simvastatin (Zocor). Rosuvastatin (Crestor) was not available at the time of this study. Compliance was assessed by the medication possession ratio, and persistence was measured by the time to discontinuation. The switching rates were derived from the proportion of patients filling a prescription other than the initial statin. Patients who were switched were less compliant by about 19 percent. 17 Statin switchers were less persistent by 20.9 percent to 48.3 percent (P<0.001), depending on the gap length used to define discontinuation. 17 Although derived from only one study in one type of setting, these data are of concern because of the small, but real incidence of statinwithdrawal effects. Acute coronary syndrome in the few months after stopping a statin abruptly has been reported. The authors of this study note that patients who change medications should be given special care to ensure compliance. 17 Another consideration in developing a statin formulary are safety and dosing restrictions.these issues tend to vary for each statin. Two adverse effects associated with statins, and of most concern, are liver dysfunction and muscle-related side effects. Both appear to be dose-related adverse effects and may occur more commonly with some statins than with others. Most studies have shown that as statin dosage is increased, particularly to the highest available dose, the incidence of adverse events increases. 18 The adverse event rates, although still low, are increased at the higher end of the dosage range. An important consideration is whether a statin chosen for formulary inclusion can be used safely at high doses to reach clinical goals. Because of the particular enzyme pathways used to metabolize certain statins, such as lovastatin and simvastatin, are more prone to be involved in significant drug interactions. Other agents are less prone to drug interactions. Metabolic drug interactions can lead to elevated statin levels in the body, which increase the risk of drug-related adverse effects. 20 Journal of Managed Care Medicine Vol. 9, No. 4
5 Exhibit 4: National Average Costs of Each Task and Aggregate Cost for the Health Plan Unit Cost/Unit No. of Patients Total (000s) Two Physician Visits $51. 10,000 $51,00 Cholesterol Panel $ ,000 $85,120 ALT/AST $ ,000 $204,80 Venipuncture $ ,000 $42,000 TOTAL $848,400 Cost/Unit represents national average Every state has a specific Cost/Unit The 10,000 patient sample was arbitrarily chosen Commercial payment is calculated as a percentage of 200 Medicare physician and clinical laboratory fees. All Medicare date are derived from the 200 Medicare Physician Fee Schedule Final Rule published in the Federal Register on Sept. 30, 2005, and Nov. 21, All physician fees are based on services performed in the physician office (nonfacility) setting. Data on file. Pfizer Inc.; New York, N.Y. Conclusion For optimal management of dyslipidemia, goal optimization and compliance with medications and non-drug measures are critical. Drug selection should be primarily based on evidence of impact on morbidity and mortality outcomes in addition to safety, overall costs, and practical patient-related concerns.the evidence is clear that aggressive, early, sustained, goal- optimized management of cardiac risk factors is beneficial and generally safe for the majority of patients. From a formulary perspective, switching statins can create a need for more physician visits, more laboratory monitoring, and reduced compliance, leading to additional costs. JMCM Karol E. Watson, MD, is assistant professor of Medicine/Cardiology, codirector, UCLA Program in Preventive Cardiology at the Geffen School of Medicine at UCLA. References 1.Greenland P,Knoll MD,Stamler J et al.major Risk Factors as Antecedents of Fatal and Nonfatal Coronary Heart Disease Events. JAMA. 2003;290: Khot UN, Khot MB, Bajzer CT et al. Prevalence of Conventional Risk Factors in Patients With Coronary Heart Disease. JAMA. 2003;290: Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens Jan;13(1 Pt 2):3S-10S. 3. Neaton JD, Blackburn H, Jacobs D et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med Jul;152(7): Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from participants in 14 randomised trials of statins. Lancet. 2005;3: ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002;288(23): The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998; 339: Shepard J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333: Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 30: Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 199;335: Serruys PW, de Feyter P, Macaya C et al. Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287: Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;31(934): Pedersen TR, Olsson AG, Faergeman O et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97(15): Scirica BM, Morrow DA, Cannon CP et al. PROVE IT-TIMI 22 investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol. 200;47(11): LaRosa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14): de Lemos JA, Blazing MA,Wiviott SD et al.a to Z investigators. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11): The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease.jama. 1984;Jan 20;251(3): Thiebaud P, Patel BV, Nichol MB, Berenbeim DM.The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005;11(11): Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003; Vol. 9, No. 4 Journal of Managed Care Medicine 21
Statins for Hyperlipidemia (High Cholesterol)
Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More informationMany asymptomatic individuals
Facts, myths and misconceptions about LDL-C and HDL-C By Michael B. Clearfield, DO Many asymptomatic individuals will succumb to cardiovascular disease (CVD), which is the leading cause of death and loss
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationBMC Med 7/19/2007; Simvastatin linked to reduced incidence of dementia, Parkinson s disease.
March 3, 2012 BD Response to FDA statement regarding Statins The Food and Drug Administration announced on Tuesday (February 28, 2012) the changes to the safety information on the labels of statins regarding
More informationJNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates. January 30, 2014
JNC-8 Blood Pressure and ACC/AHA Cholesterol Guideline Updates January 30, 2014 GOALS Review key recommendations from recently published guidelines on blood pressure and cholesterol management Discuss
More informationAt what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
European Heart Journal (2001) 22, 919 925 doi:10.1053/euhj.2000.2484, available online at http://www.idealibrary.com on At what coronary risk level is it cost-effective to initiate cholesterol lowering
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationStatin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012)
Statin Template Guidance Use of statins in primary and secondary prevention of vascular disease Endorsed by ABHB MTC for use in Gwent (October 2012) Notes relating to this guidance This guidance serves
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationInternational Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke
International Task Force for Prevention Of Coronary Heart Disease Clinical management of risk factors of coronary heart disease and stroke Economic analyses of primary prevention of coronary heart disease
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationCoronary heart disease (CHD) has an enormous
GLOBAL RISK ASSESSMENT IN CARDIOVASCULAR DISEASE * Steven P. Schulman, MD ABSTRACT Cardiovascular disease is the leading cause of mortality in the United States. Importantly, atherosclerosis begins at
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationCohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors (Statins) Final Report September 2005 The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationTherapeutic Approach in Patients with Diabetes and Coronary Artery Disease
Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,
More informationThe Intensive Statin Therapy Myth
F o c u s Michael Shechter MD MA, Roy Beigel MD, Shlomi Matetzky MD, Dov Freimark MD and Pierre Chouraqui MD Heart Institute, Sheba Medical Center, Tel Hashomer, Israel Affiliated to Sackler Faculty of
More informationEvidence-Based Secondary Stroke Prevention and Adherence to Guidelines
Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines Mitchell S.V. Elkind, MD, MS Associate Professor of Neurology Columbia University New York, NY Presenter Disclosure Information Mitchell
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationEffect of an Intervention to Increase Statin Use in Medicare Members Who Qualified for a Medication Therapy Management Program
RESEARCH Effect of an Intervention to Increase Statin Use in Medicare Members Karen M. Stockl, PharmD; Daniel Tjioe, PharmD; Sherry Gong, MS; Jenni Stroup, BA; Ann S. M. Harada, PhD, MPH; and Heidi C.
More informationLipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Amit Sachdeva, MD, a Christopher P. Cannon, MD, b Prakash C. Deedwania,
More informationWill The Coronary Calcium Score Affect the Decision To Treat With Statins?
Will The Coronary Calcium Score Affect the Decision To Treat With Statins? Amresh Raina M.D. Division of Cardiology University of Pennsylvania Disclosures No financial relationships relevant to this presentation
More informationUsing an EMR to Improve Quality of Care in a National Network
Using an EMR to Improve Quality of Care in a National Network James M. Gill, MD, MPH Associate Professor of Family Medicine Senior Scientist in Health Policy Jefferson Medical College, Philadelphia, PA
More informationPrescription Cholesterol-lowering Medication Use in Adults Aged 40 and Over: United States, 2003 2012
NCHS Data Brief No. 77 December 4 Prescription Cholesterol-lowering Medication Use in Adults Aged 4 and Over: United States, 3 2 Qiuping Gu, M.D., Ph.D.; Ryne Paulose-Ram, Ph.D., M.A.; Vicki L. Burt, Sc.M.,
More informationAfrican Americans & Cardiovascular Diseases
Statistical Fact Sheet 2013 Update African Americans & Cardiovascular Diseases Cardiovascular Disease (CVD) (ICD/10 codes I00-I99, Q20-Q28) (ICD/9 codes 390-459, 745-747) Among non-hispanic blacks age
More informationMaking Sense of the New Statin guidelines. They are more than just lowering your cholesterol!
Making Sense of the New Statin guidelines They are more than just lowering your cholesterol! No Disclosures Margaret (Peg) O Donnell DNPs, FNP, ANP B-C, FAANP Senior Nurse Practitioner South Nassau Communities
More informationACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc
ACUTE CORONARY SYNDROME By Dr wasfi al abadi md jbc, dr walid sawalha mbbs mrcp jbc ABSTRACT Objective; In this study we looked at the demographic characteristics and the frequency of the various risk
More information2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk Lynne T Braun, PhD, CNP, FAHA, FAAN Professor of Nursing, Nurse Practitioner Rush University Medical Center 2
More informationEvidence for Caution: Women and statin use
Evidence for Caution: Women and statin use By Harriet Rosenberg Danielle Allard Women and Health Protection June 2007 Permission to duplicate is granted provided credit is given and the materials are made
More informationThe largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November 2012 07:38
Bayer HealthCare has announced the initiation of the COMPASS study, the largest clinical study of its oral anticoagulant Xarelto (rivaroxaban) to date, investigating the prevention of major adverse cardiac
More informationManagement of Lipids in 2015: Just Give them a Statin?
Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation
More informationCardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg
Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg 2 nd Annual Duke Renal Transplant Symposium March 1, 2014 Durham, NC Joseph G. Rogers, M.D. Associate
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationLipid-lowering: Can ezetimibe help close the treatment gap?
REVIEW CME CREDIT RYAN C. NEAL, MD* Assistant Professor of Medicine, Baylor College of Medicine, Houston, Texas PETER H. JONES, MD Associate Professor of Medicine, Baylor College of Medicine, Houston,
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationSecondary Prevention and Rehabilitation
Secondary Prevention and Rehabilitation Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease Manohara P. J.
More informationCardiovascular disease is the leading cause of morbidity
electronic health records Implementation of an Electronic Health Record with an Embedded Quality Improvement Program to Improve the Longitudinal Care of Outpatients with Coronary Artery Disease Allan G.
More informationTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
More informationHEDIS CY2012 New Measures
HEDIS CY2012 New Measures TECHNICAL CONSIDERATIONS FOR NEW MEASURES The NCQA Committee on Performance Measurement (CPM) approved five new measures for HEDIS 2013 (CY2012). These measures provide feasible
More informationCoronary Artery Disease leading cause of morbidity & mortality in industrialised nations.
INTRODUCTION Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations. Although decrease in cardiovascular mortality still major cause of morbidity & burden of disease.
More informationAggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost
Aggressive Lowering of Blood Pressure in type 2 Diabetes Mellitus: The Diastolic Cost Naftali Stern Institute of Endocrinology, Metabolism and Hypertension Tel Aviv -Sourasky Medical Center and Sackler
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationSystolic Blood Pressure Intervention Trial (SPRINT) Principal Results
Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and
More informationPrescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital
Research Article Prescription Pattern of Anti Hypertensive Drugs used in Hypertensive Patients with Associated Type2 Diabetes Mellitus in A Tertiary Care Hospital *T. JANAGAN 1, R. KAVITHA 1, S. A. SRIDEVI
More informationADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril,
More informationCholesterol and Triglycerides What You Should Know
Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado
More informationAchieving Quality and Value in Chronic Care Management
The Burden of Chronic Disease One of the greatest burdens on the US healthcare system is the rapidly growing rate of chronic disease. These statistics illustrate the scope of the problem: Nearly half of
More informationIR Conference Call on PCSK9
IR Conference Call on PCSK9 SAR236553/REGN727 PCSK9 Antibody for Hypercholesterolemia Phase 3 ODYSSEY Program Underway November 5, 2012 1 Safe Harbor Statement This presentation contains forward-looking
More informationMY TYPE 2 DIABETES NUMBERS
BLOOD SUGAR MANAGEMENT GUIDE MY TYPE 2 DIABETES NUMBERS Understanding and Tracking the ABCs of Type 2 Diabetes 1 BLOOD MY TYPE SUGAR 2 DIABETES MANAGEMENT ABC NUMBERS GUIDE When you have type 2 diabetes,
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationORIGINAL INVESTIGATION. Screening for Statin-Related Toxicity. The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting
ORIGINAL INVESTIGATION Screening for Statin-Related Toxicity The Yield of Transaminase and Creatine Kinase Measurements in a Primary Care Setting C. Christopher Smith, MD; Lana I. Bernstein, MD; Roger
More informationEfficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis
Efficacy of cholesterol-lowering therapy in 8 686 people with diabetes in 4 randomised trials of statins: a meta-analysis Cholesterol Treatment Trialists (CTT) Collaborators* Summary Background Although
More informationLipid Management in Diabetic Patients (June 2014 version)
(June 2014 version) Background Accelerated atherosclerosis is multifactorial and begins years/decades prior to the diagnosis of type 2 diabetes: Risk for atherosclerotic events is two to four-fold greater
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More informationCardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone
James A. Stone BPHE, BA, MSc, MD, PhD, FRCPC, FAACVPR, FACC Clinical Professor of Medicine, University of Calgary Total Cardiology, Calgary Acknowledgements and Disclosures Acknowledgements Jacques Genest
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE
More informationCardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
More informationAssessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study
European Journal of Clinical Investigation (2007) 37, 925 932 DOI: 10.1111/j.1365-2362.2007.01888.x Blackwell Publishing Ltd Review Assessing risk of myocardial infarction and stroke: new data from the
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationInitiation and Adjustment of Insulin Regimens
Start with bedtime intermediateacting insulin or bedtime or morning long-acting insulin (can initiate with 10 units or 0.2 units per kg) Initiation and Adjustment of Insulin Regimens Insulin regimens should
More informationAtherosclerosis of the aorta. Artur Evangelista
Atherosclerosis of the aorta Artur Evangelista Atherosclerosis of the aorta Diagnosis Classification Prevalence Risk factors Marker of generalized atherosclerosis Risk of embolism Therapy Diagnosis Atherosclerosis
More informationLIVER FUNCTION TESTS AND STATINS
LIVER FUNCTION TESTS AND STATINS Philippe J. Zamor and Mark W. Russo Current Opinion in Cardiology 2011,26:338 341 SUMMARY Purpose of review: To discuss recent data on statins in patients with elevated
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION
European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR
More informationSecondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence
Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationTHE THIRD REPORT OF THE EXpert
SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationBarriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness
Barriers to Healthcare Services for People with Mental Disorders Cardiovascular disorders and diabetes in people with severe mental illness Dr. med. J. Cordes LVR- Klinikum Düsseldorf Kliniken der Heinrich-Heine-Universität
More informationAssociate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland
Associate Professor Patrick Kay Interventional cardiologist Middlemore, Auckland and Mercy Hospitals Auckland 14:00-14:55 WS #45: New Therapies for Lipid Management 15:05-16:00 WS #57: New Therapies for
More informationRisk factors for peripheral artery disease
www.tasc-2-pad.org Risk factors for peripheral artery disease Based on the Inter-Society Consensus Edited by Dr Denis Clement University Hospital, Ghent, Belgium Supported by an educational grant from
More informationabstract n engl j med 372;25 nejm.org June 18, 2015 2387
The new england journal of medicine established in 1812 June 18, 2015 vol. 372 no. 25 Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes Christopher P. Cannon, M.D., Michael A. Blazing, M.D.,
More informationThe Canadian Association of Cardiac
Reinventing Cardiac Rehabilitation Outside of acute care institutions, cardiovascular disease is a chronic, inflammatory process; the reduction or elimination of recurrent acute coronary syndromes is a
More informationPRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION
Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
Measure #317: Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented National Quality Strategy Domain: Community / Population Health 2016 PQRS OPTIONS F INDIVIDUAL MEASURES:
More informationA list of FDA-approved testosterone products can be found by searching for testosterone at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationHypertension and Diabetes
Hypertension and Diabetes C.W. Spellman, D.O., Ph.D., FACOI Professor & Associate Dean Research Dir. Center Diabetes & Metabolic Disorders Texas Tech University Health Science Center Midland-Odessa, Texas
More informationVitamin D and Cardiometabolic risk
Vitamin D and Cardiometabolic risk 서울의대, 분당서울대병원 내과 최 성 희 2013년 대한당뇨병학회 춘계학술대회 Metabolism Of Vitamin D Risk factors for vitamin D deficiency - Aging decreased concentrations of 7-dehydro-cholesterol in
More informationThe incidence of coronary heart disease (CHD) peaks in the elderly population. In secondary
SPECIAL ARTICLE Cholesterol Lowering in the Elderly Population Scott M. Grundy, MD, PhD; James I. Cleeman, MD; Basil M. Rifkind, MD; Lewis H. Kuller, MD, DrPH; for the Coordinating Committee of the National
More informationDuration of Dual Antiplatelet Therapy After Coronary Stenting
Duration of Dual Antiplatelet Therapy After Coronary Stenting C. DEAN KATSAMAKIS, DO, FACC, FSCAI INTERVENTIONAL CARDIOLOGIST ADVOCATE LUTHERAN GENERAL HOSPITAL INTRODUCTION Coronary artery stents are
More informationESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease
Diabetes, prediabetes and cardiovascular disease Classes of recommendations Levels of evidence Recommended treatment targets for patients with diabetes and CAD Definition, classification and screening
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationHigh Cholesterol and Heart Disease
Evaluating statin drugs to treat: High Cholesterol and Heart Disease Comparing Effectiveness, Safety, and Price Contents Our Recommendations........................................... 3 Welcome....................................................
More informationProtocol. Cardiac Rehabilitation in the Outpatient Setting
Protocol Cardiac Rehabilitation in the Outpatient Setting (80308) Medical Benefit Effective Date: 07/01/14 Next Review Date: 09/15 Preauthorization No Review Dates: 07/07, 07/08, 05/09, 05/10, 05/11, 05/12,
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationTHE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT
THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT Stroke Prevention in Atrial Fibrillation Gregory Albers, M.D. Director Stanford Stroke Center Professor of Neurology and Neurological
More informationStress is linked to exaggerated cardiovascular reactivity. 1) Stress 2) Hostility 3) Social Support. Evidence of association between these
Psychosocial Factors & CHD Health Psychology Psychosocial Factors 1) Stress 2) Hostility 3) Social Support Evidence of association between these psychosocial factors and CHD Physiological Mechanisms Stress
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationDesign and principal results
International Task Force for Prevention Of Coronary Heart Disease Coronary heart disease and stroke: Risk factors and global risk Slide Kit 1 (Prospective Cardiovascular Münster Heart Study) Design and
More informationMultiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden
Multiple comorbidities: additive and predictive of cardiovascular risk Peter M. Nilsson Lund University University Hospital Malmö, Sweden Clinical outcomes: major complications of CVD Heart Attack/ACS
More informationClinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience
International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More information